Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BALZIVA-21 vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BALZIVA-21 is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) signaling by binding to VEGF-A and preventing its interaction with VEGF receptors (VEGFR-1 and VEGFR-2), thereby reducing angiogenesis and tumor vascularization.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Treatment of metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy,Treatment of non-small cell lung cancer (first-line) in combination with carboplatin and paclitaxel,Treatment of glioblastoma as monotherapy in patients with progressive disease following prior therapy,Treatment of metastatic renal cell carcinoma in combination with interferon alfa
Prevention of pregnancy
BALZIVA-21 is administered 150 mg orally twice daily.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal half-life: 18 hours (range 12-24 hr); prolonged in renal impairment
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Metabolized by proteolytic degradation into small peptides and amino acids via catabolic pathways; not metabolized by CYP450 enzymes.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal: 70% unchanged; biliary/fecal: 20%; 10% metabolized
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
95% bound to albumin and alpha-1-acid glycoprotein
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Vd: 0.8 L/kg (reflects extensive tissue distribution)
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: 75% (first-pass effect reduces from 100%)
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
Cr Cl 30-60 m L/min: 75 mg twice daily. Cr Cl 15-29 m L/min: 75 mg once daily. Cr Cl <15 m L/min or hemodialysis: 75 mg after each dialysis session.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Child-Pugh A: no adjustment. Child-Pugh B: 75 mg twice daily. Child-Pugh C: not recommended.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not established for patients under 18 years.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
No specific adjustment; monitor renal function and consider age-related decline in Cr Cl.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Gastrointestinal perforation, wound dehiscence, and hemorrhage: BALZIVA-21 can cause serious and fatal gastrointestinal perforations, wound healing complications, and severe hemorrhage. Treatment should not be initiated for at least 28 days after major surgery and until the surgical wound is fully healed.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Gastrointestinal perforation, wound healing complications, hemorrhage, arterial thromboembolic events, venous thromboembolic events, hypertension, reversible posterior leukoencephalopathy syndrome (RPLS), infusion-related reactions, and proteinuria including nephrotic syndrome.
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Hypersensitivity to BALZIVA-21 or any excipients; untreated hypertension with systolic >150 mm Hg or diastolic >100 mm Hg; recent major surgery (within 28 days); history of arterial thromboembolic events (e.g., myocardial infarction, stroke) within 6 months; serious bleeding diathesis or coagulopathy; metastatic colorectal cancer involving the trachea, bronchi, or esophagus with cavitation or hemoptysis.
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Avoid grapefruit and grapefruit juice, which may increase BALZIVA-21 levels. No other significant dietary restrictions. Maintain consistent vitamin K intake if also taking warfarin, but not applicable as BALZIVA-21 is a factor Xa inhibitor.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
First trimester: Known teratogen. Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) with exposure. Second and third trimesters: Fetal toxicity, including oligohydramnios and fetal renal impairment, is well-documented. Avoid use throughout pregnancy unless no alternative and benefit justifies risk.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Unknown whether Balziva-21 or its metabolites are excreted in human milk. M/P ratio not available. Due to potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Increased clearance and altered volume of distribution during pregnancy may necessitate dose adjustments. Contraindicated in pregnancy, but if unavoidable, therapeutic drug monitoring and dose titration based on serum levels may be required; however, no established dosing guidelines exist.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
BALZIVA-21 is a novel oral anticoagulant (factor Xa inhibitor) with a half-life of 21 hours, allowing once-daily dosing. No routine coagulation monitoring is required. Reversal agent (andexanet alfa) is available for life-threatening bleeding. Avoid in severe hepatic impairment (Child-Pugh C). Adjust dose in renal impairment (Cr Cl <30 m L/min: reduce dose by 50%).
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take exactly as prescribed at the same time each day.,Do not stop taking without consulting your doctor, as this increases stroke risk.,Report any unusual bleeding or bruising immediately.,Avoid aspirin, NSAIDs, and other blood thinners unless directed by your doctor.,Inform all healthcare providers, including dentists, that you are taking this medication.,If a dose is missed, take it as soon as remembered if within 12 hours; otherwise skip and resume next day.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BALZIVA-21 vs ALYACEN 1/35, answered by our medical review team.
BALZIVA-21 is a Oral Contraceptive that works by BALZIVA-21 is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) signaling by binding to VEGF-A and preventing its interaction with VEGF receptors (VEGFR-1 and VEGFR-2), thereby reducing angiogenesis and tumor vascularization.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BALZIVA-21 and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BALZIVA-21 is: BALZIVA-21 is administered 150 mg orally twice daily.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BALZIVA-21 and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BALZIVA-21 is classified as Category C. First trimester: Known teratogen. Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) with exposure. Second and third trimesters: Fetal. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.